Kevin Courtney, MD, PhD, Associate Professor of Internal Medicine in the Division of Hematology and Oncology, is nominated for the CPRIT Clinical Investigator Award. Dr. Courtney is an outstanding physician who provides exceptional care to his patients. He is a leader in the field of genitourinary medical oncology, which is the treatment of patients with cancers of the genitourinary system, including prostate cancer, kidney cancer, bladder cancer, and testicular cancer. Dr. Courtney is also a first-rate clinical scientist. He leads efforts to make clinical trials available to patients with genitourinary cancers who are treated at UT Southwestern. He also develops new clinical trials and coll...

Read More

Kevin Courtney, MD, PhD, Associate Professor of Internal Medicine in the Division of Hematology and Oncology, is nominated for the CPRIT Clinical Investigator Award. Dr. Courtney is an outstanding physician who provides exceptional care to his patients. He is a leader in the field of genitourinary medical oncology, which is the treatment of patients with cancers of the genitourinary system, including prostate cancer, kidney cancer, bladder cancer, and testicular cancer. Dr. Courtney is also a first-rate clinical scientist. He leads efforts to make clinical trials available to patients with genitourinary cancers who are treated at UT Southwestern. He also develops new clinical trials and collaborates with a team of brilliant scientists to try to better understand kidney cancer and prostate cancer with the goal of improving treatments for these diseases. With his application for this CPRIT Clinical Investigator Award, Dr. Courtney is seeking funding to support his time and effort to make these contributions. He has proposed specific aims to achieve this goal: (1) contributing to the design and development of new clinical trials for patients with genitourinary cancers and making those trials available to patients at UT Southwestern; (2) studying how kidney cancer tumors use the amino acid glutamine as fuel in an effort to better understand how this can be exploited to develop potential new treatments for kidney cancer; and (3) mentoring early career clinical investigators, including clinical fellows and junior faculty physicians within his group, to train the next generation of clinical investigators dedicated to improving the treatments available to patients with genitourinary cancers.

Read Less